-
1Academic Journal
المؤلفون: Anna V. Torgashina, Anna N. Khelkovskaya-Sergeeva, Askat O. Abdykerimov, Alsu R. Khalmetova, А. В. Торгашина, А. Н. Хелковская-Сергеева, А. О. Абдыкеримов, А. Р. Хальметова
المساهمون: Исследование выполнено в рамках выполнения государственного задания по теме FURS-2022-003 (номер государ- ственного задания 1021051402790-6) «Изучение иммунопатологии, диагностики и терапии на ранних стадиях системных ревматических заболеваний».
المصدر: Rheumatology Science and Practice; Vol 62, No 4 (2024); 435–440 ; Научно-практическая ревматология; Vol 62, No 4 (2024); 435–440 ; 1995-4492 ; 1995-4484
مصطلحات موضوعية: интерстициальное поражение легких, overlap syndrome, scleroderma, Sjögren’s syndrome, myositis, interstitial lung disease, перекрестный синдром, системная склеродермия, синдром Шегрена, миозит
وصف الملف: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/3613/2395; Targoff IN. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum Dis Clin North Am. 2002;28:859-890.; Casal-Dominguez M, Pinal-Fernandez I, Derfoul A, Graf R, Michelle H, Albayda J, et al. The phenotype of myositis patients with anti-Ku autoantibodies. Semin Arthritis Rheum. 2021;51(4):728-734. doi:10.1016/j.semarthrit.2021.04.012; Belizna C, Henrion D, Beucher A, Lavigne C, Ghaali A, Lévesque H. Anti-Ku antibodies: Clinical, genetic and diagnostic insights. Autoimmun Rev. 2010;9(10):691-694. doi:10.1016/j.autrev.2010.05.020; Mimori T, Akizuki M, Yamagata H, Inada S, Yoshida S, Homma M. Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis – scleroderma overlap. J Clin Invest. 1981;68:611-620.; Mimori T. Clinical significance of anti-Ku autoantibodies – A serologic marker of overlap syndrome? Intern Med. 2002;41(12): 1096-1098. doi:10.2169/internalmedicine.41.1096; Cooley HM, Melny BJ, Gleeson R, Greco T, Kay TW. Clinical and serological associations of anti-Ku antibody. J Rheumatol. 1999;26:563-567.; Ghirardello A, Zampieri S, Iaccarino L, Tarricone E, Tonello M, Bendo R, et al. Gli anticorpi miosite specifici e miosite associati nelle miopatie infiammatorie idiopatiche: Studio sierologico di 46 pazienti [Myositis specific and myositis associated autoantibodies in idiopathic inflammatory myopathies: A serologic study of 46 patients]. Reumatismo. 2005;57(1):22-28. (In Italian). doi:10.4081/reumatismo.2005.22; Selva -O’Callaghan A, Labrador-Horrillo M, Solans-Laque R, Simeon-Aznar CP, Martínez-Gómez X, Vilardell-Tarrés M. Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy. Arthritis Rheum. 2006;55(5):791-798. doi:10.1002/art.22237; Yaneva M, Arnett FC. Antibodies against Ku protein in sera from patients with autoimmune diseases. Clin Exp Immunol. 1989;76:366-372.; McClain MT, Ramsland PA, Kaufman KM, James JA. Anti-Sm autoantibodies in systemic lupus target highly basic surface structures of complexed spliceosomal autoantigens. J Immunol. 2002;168(4):2054-2062. doi:10.4049/jimmunol.168.4.2054; Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senécal JL. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: Insights into clinical features and outcomes. Arthritis Res Ther. 2007;9(4):R78. doi:10.1186/ar2276; Arnett FC, Targoff IN, Mimori T, Goldstein R, Warner NB, Reveille JD. Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum. 1996;39(9):1507-1518. doi:10.1002/art.1780390910; Hirakata M, Mimori T, Akizuki M, Craft J, Hardin JA, Homma M. Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in Japanese patients with inflammatory muscle disease. Arthritis Rheum. 1992;35(4):449-456. doi:10.1002/art.1780350415; Wang J, Satoh M, Kabir F, Shaw M, Domingo MA, Mansoor R, et al. Increased prevalence of autoantibodies to Ku antigen in African American versus white patients with systemic lupus erythematosus. Arthritis Rheum. 2001;44(10):2367-2370. doi:10.1002/1529-0131(200110)44:103.0.co;2-i; Villalta D, Tozzoli R, Tonutti E, Bizzaro N. The laboratory approach to the diagnosis of autoimmune diseases: Is it time to change? Autoimmun Rev. 2007;6(6):359-365. doi:10.1016/j.autrev.2007.01.009; Franceschini F, Cavazzana I, Generali D, Quinzanini M, Viardi L, Ghirardello A, et al. Anti-Ku antibodies in connective tissue diseases: Clinical and serological evaluation of 14 patients. J Rheumatol. 2002;29:1393-1397.; Spielmann L, Nespola B, Séverac F, Andres E, Kessler R, Guffroy A, et al. Anti-Ku syndrome with elevated CK and anti-Ku syndrome with anti-dsDNA are two distinct entities with different outcomes. Ann Rheum Dis. 2019;78(8):1101-1106. doi:10.1136/annrheumdis-2018-214439; Lieber MR, Ma Y, Pannicke U, Schwarz K. The mechanism of vertebrate nonhomologous DNA end joining and its role in V(D)J recombination. DNA Repair. 2004;3:817-826.; Schild-Poulter C, Su A, Shih A, Kelly OP, Fritzler MJ, Goldstein R, et al. Association of autoantibodies with Ku and DNA repair proteins in connective tissue diseases. Rheumatology (Oxford). 2008;47(2):165-171. doi:10.1093/rheumatology/kem338; Rigolet A, Musset L, Dubourg O, Maisonobe T, Grenier P, Charuel JL, et al. Inflammatory myopathies with anti-Ku antibodies: A prognosis dependent on associated lung disease. Medicine (Baltimore). 2012;91(2):95-102. doi:10.1097/MD.0b013e31824d9cec; Kishi T, Miyamae T, Morimoto R, Ishiguro N, Hamaguchi Y, Fujimoto M, et al. Childhood-onset anti-Ku antibody-positive generalized morphea with polymyositis: A Japanese case study. Pediatr Dermatol. 201532(5):e224-e225. doi:10.1111/pde.12644; Meek K, Gupta S, Ramsden DA, Lees-Miller SP. The DNAdependent protein kinase: The director at the end. Immunol Rev. 2004;200:132-141. doi:10.1111/j.0105-2896.2004.00162.x; Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344-347.; van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall L, et al. 2013 classification criteria for systemic sclerosis: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747-1755. doi:10.1136/annrheumdis-2013-204424; Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/ European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017;69(1):35-45. doi:10.1002/art.39859; Fredi M, Cavazzana I, Quinzanini M, Taraborelli M, Cartella S, Tincani A, et al. Rare autoantibodies to cellular antigens in systemic lupus erythematosus. Lupus. 2014;23(7):672-677. doi:10.1177/0961203314524850; Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther. 2003;5(2):80-93. doi:10.1186/ar628; Cavazzana I, Ceribelli A, Quinzanini M, Scarsi M, Airò P, Cattaneo R, et al. Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases. Lupus. 2008;17(8):727-732. doi:10.1177/0961203308089442; Hoa S, Hudson M, Troyanov Y, Proudman S, Walker J, Stevens W, et al. Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: Clinical associations. Medicine (Baltimore). 2016;95(35):e4713. doi:10.1097/MD.0000000000004713; https://rsp.mediar-press.net/rsp/article/view/3613
-
2Academic Journal
المؤلفون: O. N. Egorova, G. M. Tarasova, G. M. Koylubaeva, A. Yu. Sukhanina, I. A. Guseva, A. M. Bolotbekova, G. Suyunbai kyzy, A. T. Turatbekova, A. A. Okunova, A. O. Abdykerimov, T. M. Reshetnyak, О. Н. Егорова, Г. М. Тарасова, Г. М. Койлубаева, А. Ю. Суханина, И. А. Гусева, А. М. Болотбекова, Г. Суйунбай кызы, А. Т. Туратбекова, А. А. Окунова, А. О. Абдыкеримов, Т. М. Решетняк
المساهمون: Статья подготовлена в рамках научно-исследовательской работы (№/№ государственных заданий РК 122040400024-7) и международного сотрудничества ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» (Россия) и Национального центра кардиологии и терапии им. акад. Мирсаида Миррахимова при Министерстве здравоохранения Кыргызской республики (Кыргызстан).
المصدر: Modern Rheumatology Journal; Том 18, № 1 (2024); 101-108 ; Современная ревматология; Том 18, № 1 (2024); 101-108 ; 2310-158X ; 1996-7012
مصطلحات موضوعية: терапия, diagnostics, disease activity, therapy, диагностика, активность заболевания
وصف الملف: application/pdf
Relation: https://mrj.ima-press.net/mrj/article/view/1539/1445; Seko Y , Takahashi N, Tada Y, et al. Restricted usage of T-cell receptor VgammaVdelta genes and expression of costimulatory molecules in Takayasu's arteritis. Int J Cardiol. 2000 Aug 31;75 Suppl 1:S77-83; discussion S85-7. doi:10.1016/s0167-5273(00)00194-7.; Ohigashi H, Haraguchi G, Konishi M, et al. Improved prognosis of Takayasu arteritis over the past decade. Circ J. 2012;76(4): 1004-11. doi:10.1253/circj.cj-11-1108. Epub 2012 Feb 2.; Schmidt J, Kermani TA, Bacani AK, et al. Diagnostic features, treatment, and outcomes of Takayasu arteritis in a US Cohort of 126 patients. Mayo Clin Proc. 2013 Aug;88(8): 822-30. doi:10.1016/j.mayocp.2013.04.025. Epub 2013 Jul 10.; Gudbrandsson B, Molberg O, Garen T, Palm O. Prevalence, Incidence, and Disease Characteristics of Takayasu Arteritis by Ethnic Background: Data From a Large, PopulationBased Cohort Resident in Southern Norway. Arthritis Care Res (Hoboken). 2017 Feb;69(2): 278-285. doi:10.1002/acr.22931. Epub 2016 Dec 31.; Watanabe Y, Miyata T, Tanemoto K. Current Clinical Features of New Patients With Takayasu Arteritis Observed From Cross-Country Research in Japan: Age and Sex Specificity. Circulation. 2015 Nov 3;132(18):1701-9. doi:10.1161/CIRCULATIONAHA.114. 012547. Epub 2015 Sep 9.; Firouzi A , Khalilipur E, Khajali Z, et al. The Treatment Dilemma of Arteriopathy in Takayasu Arteritis – A State-of-the-Art Approach. Curr Probl Cardiol. 2023 Jan; 48(1): 101359. doi:10.1016/j.cpcardiol.2022.101359.; Zhang Z, Wang W, Zhou M, et al. Observational Study of Sex Differences in Takayasu Arteritis in China: Implications for Worldwide Regional Differences. Ann Vasc Surg. 2020 Jul:66:309-317. doi:10.1016/j.avsg.2019.12.007. Epub 2019 Dec 18.; Rutter M, Bowley J, Lanyon PC, et al. A Systematic Review and Meta-Analysis of the Incidence Rate of Takayasu Arteritis. Rheumatology (Oxford). 2021; Nov 3;60(11): 4982-4990. doi:10.1093/rheumatology/ keab406.; Isohisa I, Numano F, Maezawa H, Sasazuki T. HLA-Bw52 in Takayasu disease. Tissue Antigens. 1978 Oct;12(4):246-8. doi:10.1111/j.1399-0039.1978.tb01332.x.; Naito S, Arakawa K, Saito S, et al. Takayasu's disease: association with HLA-B5. Tissue Antigens. 1978 Aug;12(2):143-5. doi:10.1111/j.1399-0039.1978.tb01310.x.; Terao C. Revisited HLA and non-HLA genetics of Takayasu arteritis – where are we? J Hum Genet. 2016 Jan;61(1):27-32. doi:10.1038/jhg.2015.87. Epub 2015 Jul 16.; Saruhan-Direskeneli G, Hughes T, Aksu K, et al. Identification of multiple genetic susceptibility loci in Takayasu arteritis. Am J Hum Genet. 2013 Aug 8;93(2):298-305. doi:10.1016/j.ajhg.2013.05.026. Epub 2013 Jul 3.; Renauer PA, Saruhan-Direskeneli G, Coit P, et al. Identification of Susceptibility Loci in IL6, RPS9/LILRB3, and an Intergenic Locus on Chromosome 21q22 in Takayasu Arteritis in a Genome-Wide Association Study. Arthritis Rheumatol. 2015 May;67(5): 1361-8. doi:10.1002/art.39035.; Renauer P, Sawalha AH. The genetics of Takayasu arteritis. Presse Med. 2017 Jul-Aug; 46(7-8 Pt 2):e179-e187. doi:10.1016/j.lpm.2016.11.031. Epub 2017 Jul 26.; Ortiz-Fernandez L, Saruhan-Direskeneli G, Alibaz-Oner F, et al. Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. Am J Hum Genet. 2021 Jan 7;108(1): 84-99. doi:10.1016/j.ajhg.2020.11.014. Epub 2020 Dec 11.; Carmona FD, Coit P, Saruhan-Direskeneli G, et al. Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy. Sci Rep. 2017 Mar 9:7:43953. doi:10.1038/srep43953.; Jin K, Wen Z, Wu B, et al. NOTCH-induced rerouting of endosomal trafficking disables regulatory T cells in vasculitis. J Clin Invest. 2021 Jan 4;131(1):e136042. doi:10.1172/JCI136042.; Daxini A, Cronin K, Sreih AG. Vasculitis associated with immune checkpoint inhibitors-a systematic review. Clin Rheumatol. 2018 Sep;37(9):2579-2584. doi:10.1007/s10067-018-4177-0. Epub 2018 Jun 19.; Pryshchep O, Ma-Krupa W, Younge BR, et al.Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation. 2008 Sep 16;118(12):1276-84. doi:10.1161/CIRCULATIONAHA.108.789172. Epub 2008 Sep 2.; Kaiser M, Younge B, Björnsson J, et al. Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells. Am J Pathol. 1999 Sep; 155(3):765-74. doi:10.1016/S0002-9440(10) 65175-9.; Desbois AC, Regnier P, Quiniou V, et al. Specific Follicular Helper T Cell Signature in Takayasu Arteritis. Arthritis Rheumatol. 2021 Jul;73(7):1233-1243. doi:10.1002/art.41672. Epub 2021 May 19.; Hoyer BF, Mumtaz IM, Loddenkemper K, et al. Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis. 2012 Jan;71(1):75-9. doi:10.1136/ard.2011.153007. Epub 2011 Sep 27.; Grayson PC, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology/ EULAR classification criteria for Takayasu arteritis. Ann Rheum Dis. 2022 Dec;81(12): 1654-1660. doi:10.1136/ard-2022-223482. Epub 2022 Nov 9.; Misra DP, Singh K, Rathore U, et al. Management of Takayasu arteritis. Best Pract Res Clin Rheumatol. 2023 May 26;101826. doi:10.1016/j.berh.2023.101826.; As C, Danda D. Current Diagnosis and Management of Takayasu Arteritis. Int Heart J. 2023;64(4):519-534. doi:10.1536/ihj.23-195.; Quinn KA, Gribbons KB, Carette S, et al. Patterns of clinical presentation in Takayasu’s arteritis. Semin Arthritis Rheum. 2020 Aug; 50(4):576-581. doi:10.1016/j.semarthrit.2020. 04.012. Epub 2020 May 19.; Keenan NG, Mason JC, Maceira A, et al. Integrated cardiac and vascular assessment in takayasu arteritis by cardiovascular magnetic resonance. Arthritis Rheum. 2009 Nov;60(11): 3501-9. doi:10.1002/art.24911.; Койлубаева ГМ, Болотбекова АМ, Бейшенкулов МТ и др. Клинические проявления поражения сердечно-сосудистой системы и предикторы неблагоприятного прогноза артериита Такаясу у кыргызских пациентов. Научно-практическая ревматология. 2023;61(5):576-583.; Hellmich B, Agueda A, Monti S, et al. 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020 Jan;79(1):19-30. doi:10.1136/annrheumdis-2019-215672. Epub 2019 Jul 3.; Maz M, Chung SA, Abril A, et al. American college of rheumatology/vasculitis foundation guideline for the management of giant cell arteritis and Takayasu Arteritis. Arthritis Rheumatol. 2021 Aug;73(8):1349-65. doi:10.1002/art.41774 31. Hoffman GS, Leavitt RY, Kerr GS, et al. Treatment of glucocorticoid-resistant or relapsing takayasu arteritis with methotrexate. Arthritis Rheum. 1994 Apr;37(4):578-82. doi:10.1002/art.1780370420.; Valsakumar AK, Valappil UC, Jorapur V, et al. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis. J Rheumatol. 2003 Aug;30(8):1793-8.; Dai D, Wang YY, Jin H, et al. The efficacy of mycophenolate mofetil in treating Takayasu arteritis: a systematic review and meta-analysis. Rheumatol Int. 2017 Jul;37(7):1083-1088. doi:10.1007/s00296-017-3704-7. Epub 2017 Mar 31.; de Souza AWS, de Almeida Agustinelli R, de Cinque Almeida H, et al. Leflunomide in Takayasu arteritis – a long term observational study. Rev Bras Reumatol Engl Ed. 2016 JulAug;56(4):371-5. doi:10.1016/j.rbre.2016.02.003. Epub 2016 Mar 2.; Sun Y, Ma L, Ma L, et al. Cyclophosphamide could be a better choice than methotrexate as induction treatment for patients with more severe Takayasu's arteritis. Rheumatol Int. 2017 Dec;37(12):2019-2026. doi:10.1007/s00296-017-3847-6. Epub 2017 Oct 13.; Misra DP, Rathore U, Patro P, et al. Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritis—a systematic review and meta-analysis. Clin Rheumatol. 2021 Nov;40(11):4391-4416. doi:10.1007/s10067-021-05743-2. Epub 2021 May 1.; Barra L, Yang G, Pagnoux C. Non-glucocorticoid drugs for the treatment of Takayasu's arteritis: A systematic review and meta-analysis. Autoimmun Rev. 2018 Jul;17(7):683-693. doi:10.1016/j.autrev.2018.01.019. Epub 2018 May 2.; Mertz P, Kleinmann JF, Lambert M, et al. Infliximab is an effective glucocorticoid-sparing treatment for Takayasu arteritis: results of a multicenter open-label prospective study. Autoimmun Rev. 2020 Oct;19(10):102634. doi:10.1016/j.autrev.2020.102634. Epub 2020 Aug 13.; Clifford A, Hoffman GS. Recent advances in the medical management of Takayasu arteritis: an update on use of biologic therapies. Curr Opin Rheumatol. 2014 Jan;26(1):7-15. doi:10.1097/BOR.0000000000000004.; Mekinian A, Comarmond C, Resche-Rigon M, et al. Efficacy of biological-targeted treatments in takayasu arteritis: multicenter, retrospective study of 49 patients. Circulation. 2015 Nov 3;132(18):1693-700. doi:10.1161/CIRCULATIONAHA.114.014321. Epub 2015 Sep 9.; Suematsu R, Tashiro S, Ono N, et al. Successful golimumab therapy in four patients with refractory Takayasu's arteritis. Mod Rheumatol. 2018 Jul;28(4):712-715. doi:10.3109/14397595.2015.1134393. Epub 2016 Mar 21.; Novikov PI, Smitienko IO, Sokolova MV, et al. Certolizumab pegol in the treatment of takayasu arteritis. Rheumatology (Oxford). 2018 Dec 1;57(12):2101-2105. doi:10.1093/rheumatology/key197.; Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum. 2008 Apr;58(4):1197-200. doi:10.1002/art.23373.; Abisror N, Mekinian A, Lavigne C, et al. Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review. Autoimmun Rev. 2013 Oct;12(12):1143-9. doi:10.1016/j.autrev.2013.06.019. Epub 2013 Jun 29.; Canas CA, Canas F, Izquierdo JH, et al. Efficacy and safety of anti-interleukin 6 receptor monoclonal antibody (tocilizumab) in colombian patients with takayasu arteritis. J Clin Rheumatol. 2014 Apr;20(3):125-9. doi:10.1097/RHU.0000000000000098.; Koster MJ, Matteson EL, Warrington KJ. Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis. Curr Opin Rheumatol. 2016 May;28(3):211-7. doi:10.1097/BOR.0000000000000265.; Wang J, Kong X, Ma L, et al. Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis: an open-label study. Rheumatology (Oxford). 2023 Aug 4:kead387. doi:10.1093/rheumatology/kead387. Online ahead of print.; Upendra Rathore U, Thakare DR, Patro P, et al. A systematic review of clinical and preclinical evidences for Janus kinase inhibitors in large vessel vasculitis. Clin Rheumatol. 2022 Jan;41(1):33-44. doi:10.1007/s10067-021-05973-4. Epub 2021 Nov 3; Kong X, Sun Y, Dai X, et al. Treatment efficacy and safety of tofacitinib vs. methotrexate in Takayasu arteritis: a prospective observational study. Ann Rheum Dis. 2022 Jan;81(1): 117-123. doi:10.1136/annrheumdis-2021-220832.; Li J, Li M, Tian X, Zeng X. Tofacitinib in patients with refractory Takayasu's arteritis. Rheumatology (Oxford). 2020 Nov 1;59(11): e95-e98. doi:10.1093/rheumatology/keaa281.; Sato S, Matsumoto H, Temmoku J, et al. A case of Takayasu arteritis complicated by refractory ulcerative colitis successfully treated with tofacitinib. Rheumatology (Oxford). 2020 Jul 1;59(7):1773-1775. doi:10.1093/rheumatology/kez580.; Palermo A, Marvisi C, Casali M, et al. Tofacitinib for the treatment of refractory Takayasu's arteritis: description of 2 cases. Clin Exp Rheumatol. 2020 Mar-Apr;38 Suppl 124(2):234-235. Epub 2020 Jan 9.; Regnier P, Le Joncour A, MaciejewskiDuval A, et al. Targeting JAK/STAT pathway in Takayasu's arteritis. Ann Rheum Dis. 2020 Jul;79(7):951-959. doi:10.1136/annrheumdis-2019-216900. Epub 2020 Mar 25.; Watanabe R. JAK inhibitors as promising agents for refractory Takayasu arteritis. Ann Rheum Dis. 2022 Apr;81(4):e67. doi:10.1136/ annrheumdis-2020-217577; Inder SJ, Bobryshev YV, Cherian SM, et al. Immunophenotypic analysis of the aortic wall in Takayasu's arteritis: involvement of lymphocytes, dendritic cells and granulocytes in immuno-inflammatory reactions. Cardiovasc Surg. 2000 Mar;8(2):141-8. doi:10.1016/s0967-2109(99)00100-3.; Galarza C, Valencia D, Tobуn GJ, et al. Should rituximab be considered as the firstchoice treatment for severe autoimmune rheumatic diseases? Clin Rev Allergy Immunol. 2008 Feb;34(1):124-8. doi:10.1007/s12016-007-8028-z.; Pazzola G, Muratore F, Pipitone N, et al. Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature. Rheumatology (Oxford). 2018 Jul 1; 57(7):1151-55. doi:10.1093/rheumatology/kex249.; Mekinian A, Noe L, Salvarani C, et al. Effectiveness and safety of rituximab in Takayasu arteritis: data from a multicenter retrospective study. Joint Bone Spine. 2023 Oct 31; 91(2):105658. doi:10.1016/j.jbspin.2023.105658.; Nakagomi D, Kronbichler A, Witte T, et al. Comment on: Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature. Rheumatology (Oxford). 2018 Jul 1;57(7):1309-1310. doi:10.1093/rheumatology/kex493.; Caltran E, Di Colo G, Ghigliotti G, et al. Two Takayasu arteritis patients successfully treated with rituximab. Clin Rheumatol. 2014 Aug;33(8):1183-4. doi:10.1007/s10067-014-2506-5. Epub 2014 Jan 31.; Mutoh T, Ishii T, Shirai T, et al. Refractory Takayasu arteritis successfully treated with rituximab: case-based review. Rheumatol Int. 2019 Nov;39(11):1989-1994. doi:10.1007/s00296-019-04390-w. Epub 2019 Aug 6.; Blache U, Tretbar S, Koehl U, et al. CAR T cells for treating autoimmune diseases. RMD Open. 2023 Nov 23;9(4):e002907. doi:10.1136/rmdopen-2022-002907.; Kwon OC, Oh JS, Park MC, et al. Statins reduce relapse rate in Takayasu arteritis. Int J Cardiol. 2019 Jul 15:287:111-115. doi:10.1016/j.ijcard.2019.02.046. Epub 2019 Feb 20.; Laurent C, Prieto-Gonzalez S, Belnou P, et al. Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis. Sci Rep. 2021 Jul 13;11(1):14404. doi:10.1038/s41598-021-93416-0.; Shi G, Hua M, Xu Q, Ren T. Resveratrol improves treatment outcome and laboratory parameters in patients with Takayasu arteritis: A randomized double-blind and placebocontrolled trial. Immunobiology. 2017 Feb; 222(2):164-168. doi:10.1016/j.imbio.2016.10.008. Epub 2016 Oct 14.; Shao N, Jia H, Li Y, Li J. Curcumin im proves treatment out come of Takayasu arteritis patients by reducing TNF-α: a randomized placebo-controlled double-blind clinical trial. Immunol Res. 2017 Aug;65(4):969-974. doi:10.1007/s12026-017-8917-z.; Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018 May;77(5):636-643. doi:10.1136/annrheumdis-2017-212649. Epub 2018 Jan 22.; Padiyar S, Manikuppam P, Kabeerdoss J, et al. Update on pregnancy in Takayasu arteritis-A narrative review. Int J Rheum Dis. 2021 Jun;24(6):758-765. doi:10.1111/1756-185X.14109. Epub 2021 Apr 18.; Chen ST, Luo CB, Guo WY, Chang FC. Endovascular management of symptomatic stenosis of supra-aortic arteries in patients with Takayasu arteritis. J Chin Med Assoc. 2021 Mar 1;84(3):303-308. doi:10.1097/JCMA.0000000000000479.; Han HS, Yoon KW, Heo SH, et al. Aortocarotid bypass in patients with Takayasu’s arteritis. Ann Surg Treat Res. 2017 Sep;93(3): 143-151. doi:10.4174/astr.2017.93.3.143. Epub 2017 Aug 30.; Xiao Y, Zhou J, Wei X, et al. Outcomes of different treatments on Takayasu’s arteritis. J Thorac Dis. 2016 Sep;8(9):2495-2503. doi:10.21037/jtd.2016.08.12.; Chen ZG, Chen YX, Diao YP, et al. Simultaneous Multi-Supra-Aortic Artery Bypass Successfully Implemented in 17 Patients with Type I Takayasu Arteritis. Eur J Vasc Endovasc Surg. 2018 Dec;56(6):903-909. doi:10.1016/j.ejvs.2018.08.044. Epub 2018 Oct 11.; Fu Y, Chen Y. Operative experience on descending aorta with Takayasu Arteritis: a review. Front Cardiovasc Med. 2023 Jun 21:10:1181285. doi:10.3389/fcvm.2023. 1181285. eCollection 2023.; https://mrj.ima-press.net/mrj/article/view/1539
-
3Academic Journal
المؤلفون: O. N. Egorova, G. M. Tarasova, G. M. Koylubaeva, A. M. Bolotbekova, I. A. Guseva, T. M. Reshetnyak, A. T. Turatbekova, G. Suyunbai kyzy, A. O. Abdykerimov, A. A. Okunova, О. Н. Егорова, Г. М. Тарасова, Г. М. Койлубаева, А. М. Болотбекова, И. А. Гусева, Т. М. Решетняк, А. Т. Туратбекова, Г. Суйунбай кызы, А. О. Абдыкеримов, А. А. Окунова
المساهمون: The article was prepared as a part of the research work (№/№ of government tasks PK 122040400024-7) and international cooperation of V.A. Nasonova Research Institute of Rheumatology (Russia) and the National Center of Cardiology and Therapy named after academician Mirsaid Mirrakhimov at the Ministry of Health of the Kyrgyz Republic (Kyrgyz Republic)., Статья подготовлена в рамках научно-исследовательской работы (№/№ государственных заданий РК 122040400024-7) и международного сотрудничества ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» (Россия) и Национального центра кардиологии и терапии им. академика Мирсаида Миррахимова при Министерстве здравоохранения Кыргызской республики (Кыргызстан).
المصدر: Modern Rheumatology Journal; Том 17, № 6 (2023); 122-127 ; Современная ревматология; Том 17, № 6 (2023); 122-127 ; 2310-158X ; 1996-7012
مصطلحات موضوعية: рекомендации EULAR 2023 г, giant cell arteritis, visualization methods, EULAR recommendations 2018, EULAR recommendations 2023, гигантоклеточный артериит, методы визуализации, рекомендации EULAR 2018 г
وصف الملف: application/pdf
Relation: https://mrj.ima-press.net/mrj/article/view/1512/1428; Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 2013 Jan;65(1):1-11. doi:10.1002/art.37715.; Pugh D, Karabayas M, Basu N, et al. Large-vessel vasculitis. Nat Rev Dis Primers. 2022 Jan 6;7(1):93. doi:10.1038/s41572-021-00327-5.; Stone JR, Bruneval P, Angelini A, et al. Consensus statement on surgical pathology of the aorta from the Society for Cardiovascular Pathology and the Association for European Cardiovascular Pathology: I. Inflammatory diseases. Cardiovasc Pathol. 2015 Sep-Oct; 24(5):267-78. doi:10.1016/j.carpath.2015.05.001. Epub 2015 May 16.; Shima N, Nagashima T, Iwamoto M, Minota S. Comment on: retrospective analysis of 95 patients with large vessel vasculitis: a single center experience. Int J Rheum Dis. 2017 Dec; 20(12):2211-2213. doi:10.1111/1756-185X.12945. Epub 2016 Aug 12.; Furuta S, Cousins C, Chaudhry A, Jayne D. Clinical features and radiological findings in large vessel vasculitis: are Takayasu arteritis and giant cell arteritis 2 different diseases or a single entity? J Rheumatol. 2015 Feb;42(2): 300-8. doi:10.3899/jrheum.140562. Epub 2014 Nov 15.; Langford CA, Cuthbertson D, Ytterberg SR, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol. 2017 Apr;69(4):837-845. doi:10.1002/art.40044. Epub 2017 Mar 3.; Langford CA, Cuthbertson D, Ytterberg SR, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of Takayasu arteritis. Arthritis Rheumatol. 2017 Apr;69(4):846-853. doi:10.1002/art.40037. Epub 2017 Mar 8.; Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018 May;77(5):636-643. doi:10.1136/annrheumdis-2017-212649. Epub 2018 Jan 22.; Maz M, Chung SA, Abril A, et al. 2021 American college of rheumatology/vasculitis foundation guideline for the management of giant cell arteritis and takayasu arteritis. Arthritis Care Res (Hoboken). 2021 Aug;73(8): 1071-1087. doi:10.1002/acr.24632. Epub 2021 Jul 8.; Mackie SL, Dejaco C, Appenzeller S, et al. British society for rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. Rheumatology (Oxford). 2020 Mar 1;59(3):487-494. doi:10.1093/rheumatology/kez664.; Haaversen AB, Brekke LK, Bakland G, et al. Norwegian society of rheumatology recommendations on diagnosis and treatment of patients with giant cell arteritis. Front Med (Lausanne). 2023 Jan 6:9:1082604. doi:10.3389/fmed.2022.1082604. eCollection 2022.; Dejaco C, Ramiro S, Bond M, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. Ann Rheum Dis. 2023 Aug 7:ard-2023-224543. doi:10.1136/ard-2023- 224543. Online ahead of print.; Bosch P, Bond M, Dejaco C, et al. Imaging in diagnosis, monitoring and outcome prediction of large vessel vasculitis: a systematic literature review and meta-analysis informing the 2023 update of the EULAR recommendations. Ann Rheum Dis. 2023;82:124-5. doi:10.1136/annrheumdis-2023-eular.1046.; Chrysidis S, Døhn UM, Terslev L, et al. Diagnostic accuracy of vascular ultrasound in patients with suspected giant cell arteritis (EUREKA): a prospective, multicentre, nonInterventional, cohort study. The Lancet Rheumatology. 2021;3:e865–73. doi:10.1016/S2665-9913(21)00246-0.; Luqmani R, Lee E, Singh S, et al. The role of ultrasound compared to biopsy of temporal arteries in the diagnosis and treatment of giant cell arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health Technol Assess. 2016 Nov;20(90):1-238. doi:10.3310/hta20900.; Germanт G, Monti S, Ponte C, et al. The role of ultrasound in the diag-nosis and follow-up of large-vessel vasculitis: an update. Clin Exp Rheumatol. 2017 Mar-Apr;35 Suppl 103(1):194-198. Epub 2017 Mar 29.; Li D, Lin J, Yan F. Detecting disease extent and activity of Takayasu arte-ritis using whole-body magnetic resonance angiography and vessel wallimaging as a 1-stop solution. J Comput Assist Tomogr. 2011 Jul-Aug;35(4): 468-74. doi:10.1097/RCT.0b013e 318222d698.; Bezerra Lira-Filho E, Campos O, Lazaro Andrade J, et al. Thoracic aorta evaluation in patients with takayasu's arteritis by transesophageal echocardiography. J Am Soc Echocardiogr. 2006 Jun;19(6):829-34. doi:10.1016/j.echo.2005.12.023.; Nienhuis PH, Sandovici M, Glaudemans AW, et al . Visual and semiquantitative assessment of cranial artery inflammation with FDG-PET/ CT in giant cell arteritis. Semin Arthritis Rheum. 2020 Aug;50(4):616-623. doi:10.1016/j.semarthrit.2020.04.002. Epub 2020 Jun 2.; Nielsen BD, Hansen IT, Kramer S, et al. Simple dichotomous assessment of cranial artery inflammation by conventional 18F-FDG PET/CT shows high accuracy for the diagnosis of giant cell arteritis: a case-control study. Eur J Nucl Med Mol Imaging. 2019 Jan;46(1): 184-193. doi:10.1007/s00259-018-4106-0. Epub 2018 Jul 31.; van der Geest KSM, Treglia G, Glaudemans AWJM, et al. Diagnostic value of [18F]FDG-PET/CT for treatment monitoring in large vessel vasculitis: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):3886-3902. doi:10.1007/s00259-021-05362-8.; Yang Y, Wang Y, Lin J, et al. The diagnostic value of FDG PET/CT in Takayasu arteritis. J Nucl Cardiol. 2022 Aug;29(4):2029- 2030. doi:10.1007/s12350-020-02412-w.; Юдин ВИ. Ошибки в диагностике и результаты лечения больных неспецифическим аортоартериитом. Автореф. дисс. докт. мед. наук. Москва; 1993. С. 7-14.; Imfeld S, Aschwanden M, Rottenburger C, et al. [18F]FDG positron emission tomography and ultrasound in the diagnosis of giant cell arteritis: congruent or complementary imaging methods. Rheumatology (Oxford). 2020 Apr 1;59(4):772-778. doi:10.1093/rheumatology/kez362.; Nielsen BD, Hansen IT, Keller KK, et al. Diagnostic accuracy of ultrasound for detecting large-vessel giant cell arteritis using FDG PET/CT as the reference. Rheumatology (Oxford). 2020 Aug 1;59(8):2062-2073. doi:10.1093/rheumatology/kez568.; Quinn KA, Ahlman MA, Malayeri AA, et al. Comparison of magnetic resonance angiography and 18F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis. Ann Rheum Dis. 2018 Aug;77(8):1165- 1171. doi:10.1136/annrheumdis-2018- 213102. Epub 2018 Apr 17.; American College of Radiology. ACR manual on contrast media. https://www.acr.org/media/ACR/Files/Clinical-Resources/ContrastMedia.pdf; Griner PF, Mayewski RJ, Mushlin AI, et al. Selection and interpretation of diagnostic tests and procedures. Ann Intern Med. 1981 Apr;94(4 Pt 2):557-92.; Fernandez-Fernandez E, Monjo-Henry I, Bonilla G, et al. False positives in the ultrasound diagnosis of giant cell arteritis: some diseases can also show the halo sign. Rheumatology (Oxford). 2020 Sep 1;59(9):2443-2447. doi:10.1093/rheumatology/kez641.; Lötscher F, Pop R, Seitz P, et al. Spectrum of Large- and medium-vessel vasculitis in adults: neoplastic, infectious, drug-induced, autoinflammatory, and primary immunodeficiency diseases. Curr Rheumatol Rep. 2022 Oct; 24(10):293-309. doi:10.1007/s11926-022-01083-5. Epub 2022 Aug 3.; Molina Collada J, Ruiz Bravo-Burguillos E, Monjo I, et al. Positive ultrasound halo sign of temporal arteries due to amyloidosis. Rheumatology (Oxford). 2019 Nov 1;58(11):2067- 2069. doi:10.1093/rheumatology/kez182.; Nielsen BD, Gormsen LC, Hansen IT, et al. Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy. Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1119- 1128. doi:10.1007/s00259-018-4021-4.; Ponte C, Serafim AS, Monti S, et al. Early variation of ultrasound halo sign with treatment and relation with clinical features in patients with giant cell arteritis. Rheumatology (Oxford). 2020 Dec 1;59(12):3717-3726. doi:10.1093/rheumatology/keaa196.; Habib HM, Essa AA, Hassan AA. Color duplex ultrasonography of temporal arteries: role in diagnosis and follow-up of suspected cases of temporal arteritis. Clin Rheumatol. 2012 Feb;31(2):231-7. doi:10.1007/s10067-011-1808-0. Epub 2011 Jul 9.; Gunawardene AR, Chant H. Facial nerve injury during temporal artery biopsy. Ann R Coll Surg Engl. 2014 May;96(4):257-60. doi:10.1308/003588414X13814021679438.; Dejaco C, Kerschbaumer A, Aletaha D, et al. Treat-to-target recommendations in giant cell arteritis and Polymyalgia Rheumatica. Ann Rheum Dis. 2023 Feb 24:ard-2022- 223429. doi:10.1136/ard-2022-223429. Online ahead of print.; https://mrj.ima-press.net/mrj/article/view/1512